SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 227 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $413,145 | -48.2% | 13,744 | -38.5% | 0.00% | -57.1% |
| Q4 2022 | $797,581 | -16.9% | 22,360 | -32.7% | 0.01% | -12.5% |
| Q2 2022 | $960,000 | +366.0% | 33,208 | +329.2% | 0.01% | +700.0% |
| Q3 2021 | $206,000 | -49.6% | 7,737 | -41.8% | 0.00% | -50.0% |
| Q2 2021 | $409,000 | +7.3% | 13,293 | -8.6% | 0.00% | -33.3% |
| Q1 2021 | $381,000 | -59.5% | 14,548 | -61.1% | 0.00% | -50.0% |
| Q4 2020 | $941,000 | +214.7% | 37,394 | +160.8% | 0.01% | +200.0% |
| Q3 2020 | $299,000 | -32.4% | 14,337 | -22.9% | 0.00% | -33.3% |
| Q2 2020 | $442,000 | +24.9% | 18,590 | -5.3% | 0.00% | -25.0% |
| Q1 2020 | $354,000 | -29.9% | 19,630 | -7.8% | 0.00% | 0.0% |
| Q4 2019 | $505,000 | -32.0% | 21,280 | -21.2% | 0.00% | -33.3% |
| Q3 2019 | $743,000 | -74.1% | 27,015 | -68.8% | 0.01% | -73.9% |
| Q2 2019 | $2,865,000 | -0.7% | 86,581 | +5.2% | 0.02% | -4.2% |
| Q1 2019 | $2,885,000 | +18.4% | 82,339 | +12.2% | 0.02% | +14.3% |
| Q4 2018 | $2,437,000 | -44.4% | 73,370 | -15.7% | 0.02% | -27.6% |
| Q3 2018 | $4,384,000 | -9.1% | 87,080 | +8.1% | 0.03% | -9.4% |
| Q2 2018 | $4,822,000 | +5.6% | 80,559 | -19.2% | 0.03% | +190.9% |
| Q1 2018 | $4,568,000 | +5.9% | 99,739 | -7.9% | 0.01% | +10.0% |
| Q4 2017 | $4,312,000 | -11.7% | 108,257 | -11.3% | 0.01% | -9.1% |
| Q3 2017 | $4,882,000 | +7.7% | 122,049 | +16.1% | 0.01% | -8.3% |
| Q2 2017 | $4,533,000 | +30.8% | 105,153 | -5.0% | 0.01% | +33.3% |
| Q1 2017 | $3,465,000 | +14.7% | 110,727 | -7.5% | 0.01% | 0.0% |
| Q4 2016 | $3,022,000 | -33.5% | 119,662 | -34.9% | 0.01% | -35.7% |
| Q3 2016 | $4,545,000 | +5.0% | 183,780 | -13.5% | 0.01% | 0.0% |
| Q2 2016 | $4,327,000 | +26.3% | 212,394 | -5.5% | 0.01% | +27.3% |
| Q1 2016 | $3,426,000 | -7.6% | 224,671 | -18.6% | 0.01% | 0.0% |
| Q4 2015 | $3,708,000 | +4.6% | 275,877 | +9.2% | 0.01% | 0.0% |
| Q3 2015 | $3,546,000 | -13.2% | 252,745 | +5.1% | 0.01% | +10.0% |
| Q2 2015 | $4,084,000 | +3247.5% | 240,536 | +2050.1% | 0.01% | – |
| Q2 2014 | $122,000 | +19.6% | 11,187 | -2.2% | 0.00% | – |
| Q1 2014 | $102,000 | – | 11,436 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |